Business Context and Reporting Period
This Form 8-K Current Report was filed by Xeris Biopharma Holdings, Inc. (XERS) on June 29, 2026. The filing reports corporate governance changes effective July 1, 2026, including the appointment of a new director and adjustments to the Board leadership structure.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Initial Equity Award: Approximately $450,000 in combined grant date fair value (options and restricted stock units) for the new director.
- Future Annual Equity Grant: Approximately $300,000 in grant date fair value, commencing at the 2027 annual meeting.
Material Changes
The following material changes to the Board of Directors were announced:
- Board Expansion: The Board size increased from seven to eight members.
- New Director Appointment: Nerissa Kreher, M.D., was appointed as a Class III director. Her term expires at the 2027 annual meeting. She brings extensive experience as a Chief Medical Officer at various biotechnology firms, including Alltrna, Entrada Therapeutics, and Tiburio Therapeutics.
- Leadership Restructuring: John Shannon, CEO, was appointed Chairperson of the Board. Marla S. Persky was designated as Lead Independent Director.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of material risks and contingencies. It is strictly a disclosure of personnel changes and related compensatory arrangements. The filing references a press release issued on June 30, 2026, for further details on the appointments.
Investor Verification Checklist
- Verify the independence status of Dr. Kreher under Nasdaq listing standards as affirmed by the Board.
- Review the vesting schedule for the initial $450,000 equity award (three equal annual installments).
- Confirm the impact of the new Board leadership structure on future strategic decisions.
- Check the referenced 2026 Definitive Proxy Statement (Schedule 14A) for full details on the non-employee director compensation program.